var data={"title":"Heparin (unfractionated): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Heparin (unfractionated): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6307?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">see &quot;Heparin (unfractionated): Drug information&quot;</a> and <a href=\"topic.htm?path=heparin-unfractionated-patient-drug-information\" class=\"drug drug_patient\">see &quot;Heparin (unfractionated): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178752\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hep Flush-10 [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178753\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Heparin Leo;</li>\n      <li>Heparin Lock Flush;</li>\n      <li>Heparin Sodium Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053161\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticoagulant</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442594\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Many concentrations of heparin are available and range from 1 to 20,000 units/mL. Carefully examine each prefilled syringe, bag, or vial prior to use to ensure that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of IV devices and is not to be used for anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Central line flush; patency (intermittent doses):</i> Limited data available: Various recommendations exist for intermittent flushes of heparin used to maintain patency of single and double lumen central catheters; dose of heparin flush used should not approach therapeutic unit per kg dose; refer to institution specific protocols. In neonates, the 10 units/mL concentration is used with frequency and volume of flushing determined by the type of catheter; capped polyvinyl chloride catheters and peripheral heparin locks require flushing more frequently (eg, every 6 to 8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater) or may be standardized according to specific NICU policy (eg, 0.5 to 1 mL/flush). Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter (Cloherty 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Central venous access device (CVAD), patency:</i> Continuous IV infusion: 0.5 unit/kg/hour (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ECMO; venoarterial (VA)/Cardiac, anticoagulation:</i> <b>Note:</b> While used to prevent thrombosis, full anticoagulation dosing is necessary; IV: 100 units/kg prior to ECMO cannulation followed by continuous heparin infusion to maintain the ACT between 180 and 220 seconds; ACT should be checked hourly while patient is on ECMO; additional monitoring targets for heparin therapy are prolongation of the PTT to 1.5 to 2.5 times the control value or an anti-Xa level of 0.3 to 0.7 units/mL (AHA [Giglia 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Parenteral nutrition (PN) additive, venous access patency:</i> 0.5 to 1 unit/mL (final heparin concentration in the PN solution), both central and peripheral PN solutions. The final concentration of heparin used for PN solutions may need to be decreased in small neonates receiving larger PN volumes in order to avoid approaching therapeutic amounts (Corkins 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Peripheral arterial catheters in situ:</i> Intra-arterial (via arterial catheter): Continuous infusion of heparin at a final concentration of 5 units/mL at 1 mL/hour (ACCP [Monagle 2012]; Butt 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Umbilical artery catheter (UAC):</i> Intra-arterial (via UAC): Continuous infusion of heparin at a final concentration of 0.25 to 1 unit/mL; total heparin dose of 25 to 200 units/kg/day to maintain patency (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Thromboprophylaxis in CHD patients with systemic to pulmonary artery shunts (eg, Sano shunt, Blalock-Taussig shunt, central shunt) or central venous lines in certain CHD patients (eg, previous thrombosis or hypercoagulable state):</i> Low dose: Continuous IV infusion: 10 to 15 units/kg/hour (AHA [Giglia 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thrombosis; treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic heparinization:</i> IV: Initial loading dose: 75 units/kg over 10 minutes; then initial continuous maintenance infusion at 28 units/kg/hour; adjust dose to maintain an anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or a protamine titration range of 0.2 to 0.4 units/mL (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Because of variation among hospitals with reagents (lot numbers) and corresponding control of aPTT values, individual institutions should establish unique, institution-specific nomograms based on current reagent. Due to extensive variability within reagents and anti-Xa levels with corresponding aPTTs, a specific nomogram has not been provided; refer to guidelines for a specific nomogram (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic to pulmonary artery shunt thrombosis (eg, Sano shunt, Blalock-Taussig shunt, central shunt); treatment in CHD patients:</i> 50 to 100 units/kg, ongoing continuous infusion should be considered (AHA [Giglia 2013])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053153\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">see &quot;Heparin (unfractionated): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Many concentrations of heparin are available and range from 1 to 20,000 units/mL. Carefully examine each prefilled syringe, bag, or vial prior to use to ensure that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of IV devices and is not to be used for anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Central line flush; patency (intermittent doses):</i> Limited data available (ACCP [Monagle 2012]; Conway 2014; Lee 2005): Infants, Children, and Adolescents: When using intermittent flushes of heparin to maintain patency of single and double lumen central catheters, various recommendations exist; refer to institution specific protocols. Capped polyvinyl chloride catheters and peripheral heparin locks require flushing more frequently (eg, every 6 to 8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater). Dose of heparin flush used should not approach therapeutic unit per kg dose. Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>ECMO venoarterial (VA)/Cardiac, anticoagulation:</i> <b>Note:</b> While used to prevent thrombosis, full anticoagulation dosing is necessary; Infants, Children, and Adolescents: IV: 100 units/kg prior to ECMO cannulation followed by continuous IV heparin infusion to maintain the ACT between 180 and 220 seconds; ACT should be checked hourly while patient is on ECMO; additional monitoring targets for heparin therapy are prolongation of the PTT to 1.5 to 2.5 times the control value or an anti-Xa level of 0.3 to 0.7 units/mL (AHA [Giglia 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Parenteral nutrition (PN) additive, venous access patency:</i> Infants, Children, and Adolescents: 1 unit/mL (final heparin concentration in PN), both central and peripheral. The final concentration of heparin used for PN solutions may need to be decreased to 0.5 units/mL in small infants receiving larger PN volumes in order to avoid approaching therapeutic amounts (Corkins 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Peripheral arterial catheters in situ:</i> Infants and Children: Intra-arterial (via arterial catheter): Continuous infusion of heparin at a final concentration of 5 units/mL at 1 mL/hour (ACCP [Monagle 2012]; Butt 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Thromboprophylaxis in CHD patients with systemic to pulmonary artery shunts (eg, Sano shunt, Blalock-Taussig shunt, central shunt) or central venous lines in certain CHD patients (eg, previous thrombosis or hypercoagulable states):</i> Infants, Children, and Adolescents: Low Dose: Continuous IV infusion: 10 to 15 units/kg/hour (AHA [Giglia 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Thrombosis, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Systemic heparinization: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: Initial loading dose: 75 units/kg over 10 minutes; then initial continuous maintenance infusion at: 28 units/kg/hour; adjust dose to maintain an anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or a protamine titration range of 0.2 to 0.4 units/mL (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: IV: Initial loading dose: 75 units/kg over 10 minutes, then initial continuous maintenance infusion at: 20 units/kg/hour; adjust dose to maintain an anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or a protamine titration range of 0.2 to 0.4 units/mL (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Because of variation among hospitals with reagents (lot numbers) and corresponding control of aPTT values, individual institutions should establish unique, institution-specific nomograms based on current reagent. Due to extensive variability within reagents and anti-Xa levels with corresponding aPTTs, a specific nomogram has not been provided; refer to guidelines for a specific nomogram (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Systemic to pulmonary artery shunt thrombosis (eg, Sano shunt, Blalock-Taussig shunt, central shunt); treatment in CHD patients:</i> Infants, Children, and Adolescents: IV: 50 to 100 units/kg, ongoing continuous infusion should be considered (AHA [Giglia 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anticoagulation (intermittent administration):</b> IV: Initial: 10,000 units, then 50 to 70 units/kg (5,000 to 10,000 units) every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Maintenance of line patency (line flushing):</b> When using daily flushes of heparin to maintain patency of single and double lumen central catheters, 100 units/mL is used for adults. Capped PVC catheters and peripheral heparin locks require flushing more frequently (eg, every 6 to 8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater). Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition:</b> Addition of heparin (0.5 to 3 unit/mL) to peripheral and central parenteral nutrition has not been shown to decrease catheter-related thrombosis. Arterial lines are heparinized with a final concentration of 1 unit/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Thromboprophylaxis (low dose heparin):</b> SubQ: 5,000 units every 8 to 12 hours. <b>Note:</b> The American College of Chest Physicians recommends a minimum of 10 to 14 days for patients undergoing total hip arthroplasty, total knee arthroplasty, or hip fracture surgery (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178727\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25,000 units/500 mL in NaCl 0.9% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 units (500 mL); 2000 units (1000 mL); 12,500 units (250 mL); 25,000 units (250 mL, 500 mL); 1000 units/mL (1 mL, 10 mL, 30 mL); 2500 units/mL (10 mL [DSC]); 5000 units/mL (1 mL, 10 mL); 10,000 units/mL (1 mL, 4 mL, 5 mL); 20,000 units/mL (1 mL); 1000 units (500 mL); 2000 units (1000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 units/mL (2 mL); 5000 units/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hep Flush-10: 10 units/mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10,000 units (250 mL); 12,500 units (250 mL [DSC]); 20,000 units (500 mL); 25,000 units (250 mL, 500 mL); 1 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL); 2 units/mL (3 mL [DSC]); 10 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL, 30 mL [DSC]); 100 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL, 30 mL [DSC]); 2000 units/mL (5 mL [DSC]); 100 units/100 mL in NaCl 0.45% (100 mL); 1000 units/L in NaCl 0.9% (1000 mL); 15,000 units/500 mL in NaCl 0.9% (500 mL); 2000 units/500 mL in NaCl 0.9% (500 mL); 25,000 units/250 mL in Dextrose 5% (250 mL); 25,000 units/250 mL in NaCl 0.9% (250 mL); 25,000 units/500 mL in Dextrose 5% (500 mL); 250 units/250 mL in NaCl 0.45% (250 mL); 30,000 units/1000 mL in NaCl 0.9% (1000 mL); 4000 units/1000 mL in NaCl 0.9% (1000 mL); 500 units/250 mL in NaCl 0.45% (250 mL); 5000 units/500 mL in NaCl 0.9% (500 mL); 6000 units/1000 mL in NaCl 0.9% (1000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 units/mL (3 mL [DSC]); 10 units/mL (1 mL, 3 mL, 5 mL); 100 units/mL (1 mL, 3 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10,000 units/10 mL (10 mL); 20 units/20 mL in NaCl 0.9% (20 mL); 3000 units/3 mL (3 mL); 50 units/50 mL in NaCl 0.45% (50 mL); 5000 units/5 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178711\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053166\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Many concentrations of heparin are available and range from 1 to 20,000 units/mL. Carefully examine each prefilled syringe, bag, or vial prior to use to ensure that the correct concentration is chosen. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Do <b>not</b> administer IM due to pain, irritation, and hematoma formation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Infuse via infusion pump. IV bolus should be administered over 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\"> Heparin lock: Inject via injection cap using positive pressure flushing technique. Heparin lock \tflush solution is intended only to maintain patency of IV devices and is <b>not</b> to be used for anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central venous catheters: Must be flushed with heparin solution when newly inserted, daily (at the time of tubing change), after blood withdrawal or transfusion, and after an \tintermittent infusion through an injectable cap. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Not all preparation intended for SubQ administration, verify product selection. Inject in subcutaneous tissue only (not muscle tissue). Injection sites should be rotated (usually left and right portions of the abdomen, above iliac crest) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472659\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> Maintenance of line patency: 0.5 unit/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472658\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 100 units/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178745\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Heparin solutions are colorless to slightly yellow. Minor color variations do not affect therapeutic efficacy. Heparin should be stored at room temperature. Protect from freezing and temperatures &gt;40&deg;C.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Stability at room temperature and refrigeration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prepared bag: 24 to 72 hours (specific to solution, concentration, and/or study conditions)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Premixed bag: After seal is broken, 4 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Out of overwrap stability: 30 days. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053165\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Systemic: Injection: Prophylaxis and treatment of thromboembolic disorders and anticoagulant for extracorporeal and dialysis procedures (FDA approved in pediatric patients [age not specified] and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Heparin lock flush solution: Maintain patency of IV devices (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178805\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Heparin may be confused with Hespan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">National Patient Safety Goals:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The 100 unit/mL concentration should not be used to flush heparin locks, IV lines, or intra-arterial lines in neonates or infants &lt;10 kg (systemic anticoagulation may occur). The 10 unit/mL flush concentration may inadvertently cause systemic anticoagulation in infants &lt;1 kg who receive frequent flushes.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heparin sodium injection 10,000 units/mL and  Hep-Lock U/P 10 units/mL have been confused with each other. Fatal medication errors have occurred between the two whose labels are both blue. <b>Never rely on color as a sole indicator to differentiate product identity.</b></p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Labeling changes: Effective May 1st, 2013, heparin labeling is required to include the total amount of heparin per vial (rather than only including the amount of heparin per mL). During the transition, hospitals should consider only stocking the newly labeled heparin to avoid potential errors and confusion with the older labeling. </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heparin lock flush solution is intended only to maintain patency of IV devices and is <b>not</b> to be used for anticoagulant therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178802\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Immunologically mediated heparin-induced thrombocytopenia (HIT) occurs in a small percentage of patients, and is marked by a progressive fall in platelet counts and, in some cases, thromboembolic complications (skin necrosis, pulmonary embolism, gangrene of the extremities, cerebrovascular accident, or myocardial infarction).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, shock (including hemorrhagic shock), thrombosis, vasospasm (allergic; possibly related to thrombosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dysesthesia (feet), headache, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermal ulcer (rarely reported with deep subcutaneous injections; intramuscular injection [not recommended] is associated with a higher incidence of this effect), eczema, erythematous plaques (case reports), localized erythema (rarely reported with deep subcutaneous injections; intramuscular injection [not recommended] is associated with a higher incidence of this effect), skin necrosis, transient alopecia (delayed), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adrenal hemorrhage, hyperkalemia (suppression of aldosterone synthesis), hyperlipidemia (rebound; on discontinuation), ovarian hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, hematemesis, melena, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Erectile dysfunction (frequent or persistent erection), hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise (unexplained), gingival hemorrhage, hematoma (rarely reported with deep subcutaneous injections; intramuscular injection [not recommended] is associated with a higher incidence of this effect), hemorrhage, pulmonary hemorrhage, purpura, retroperitoneal hemorrhage, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation, local pain (rarely reported with deep subcutaneous injections; intramuscular injection [not recommended] is associated with a high incidence of these effects)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Osteoporosis (chronic therapy effect)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Allergic conjunctivitis, lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchospasm (case reports), epistaxis, hemoptysis, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug tolerance, fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178735\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to heparin or any component of the formulation (unless a life-threatening situation necessitates use and use of an alternative anticoagulant is not possible); severe thrombocytopenia; history of heparin-induced thrombocytopenia (HIT); uncontrolled active bleeding except when due to disseminated intravascular coagulation (DIC); cases where the administration of sodium or chloride could be clinically detrimental (applies to large volume heparin 2 unit/mL IV solutions only); not for use when appropriate blood coagulation tests cannot be obtained at appropriate intervals (applies to full-dose heparin only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> Some products contain benzyl alcohol as a preservative; their use in neonates, infants, or pregnant or breast-feeding mothers is contraindicated by some manufacturers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178715\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: May occur, including fatal events. Use with caution in patients with an increased risk of bleeding, including subacute bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; continuous GI tube drainage; severe uncontrolled hypertension; history of hemorrhagic stroke; use shortly after brain, spinal, or ophthalmologic surgery or other invasive procedures including spinal tap or spinal anesthesia; concomitant treatment with platelet inhibitors; recent GI bleeding; impaired hemostasis; thrombocytopenia or platelet defects; patients with hereditary antithrombin deficiency receiving concurrent antithrombin replacement therapy; severe liver disease; hypertensive or diabetic retinopathy; renal failure; or in patients (especially women) &gt;60 years of age. Monitor patient closely for signs or symptoms of bleeding. Discontinue if bleeding occurs; severe hemorrhage or overdosage may require protamine (consult Protamine monograph for dosing recommendations).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heparin resistance: Dose requirements &gt;35,000 units/24 hours to maintain a therapeutic aPTT may occur in patients with antithrombin deficiency, increased heparin clearance, elevations in heparin-binding proteins, elevations in factor VIII and/or fibrinogen; frequently encountered in patients with fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, MI, cancer, and in postsurgical patients; measurement of anticoagulant effects using antifactor Xa levels may be of benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia by suppressing aldosterone production.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: May occur; only in life-threatening situations when use of an alternative anticoagulant is not possible should heparin be cautiously used in patients with a documented hypersensitivity reaction. Some products are derived from animal tissue and may be contraindicated in patients with animal allergies (ie, pork); consult individual prescribing information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: May occur with prolonged use (&gt;6 months) due to a reduction in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: May occur. Heparin-induced thrombocytopenia (HIT), a serious antibody-mediated reaction resulting from irreversible aggregation of platelets, may also occur. Patients who develop HIT may be at risk of developing a new thrombus (heparin-induced thrombocytopenia and thrombosis [HITT]). Monitor platelets closely; discontinue therapy and consider alternatives if platelets are &lt;100,000/mm<sup>3</sup> and/or thrombosis develops. HIT or HITT may be delayed and can occur up to several weeks after discontinuation of heparin. Use with extreme caution (for a limited duration) or avoid in patients with history of HIT, especially if administered within 100 days of HIT episode (Dager 2007; Warkentin 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients &gt;60 years of age, particularly women; older adults can be more sensitive to heparin and a higher incidence of bleeding has been reported in these patients. May require lower doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol as a preservative. In neonates, large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;); the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling. Use in neonates, infants, or pregnant or nursing mothers is contraindicated by some manufacturers; the use of preservative-free heparin is, therefore, recommended in these populations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some preparations contain sulfite which may cause allergic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fatal medications errors: Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Clinicians <b>must</b> carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen; fatal hemorrhages have occurred related to heparin overdose especially in pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022558\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Confirm the concentration of all heparin injection vials prior to administration; do not use heparin injection as a &quot;catheter lock flush&quot; as the injection is supplied in various concentrations including highly concentrated strengths. Fatal hemorrhages have occurred in pediatric patients when higher concentrations of heparin injection were confused with lower concentrations of heparin lock flush. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Heparin-induced thrombocytopenia (HIT) has been reported in pediatric patients; incidence and risk factors are not well-defined due to variability related to patient inclusion and laboratory techniques; incidence rates up to 2.3% in PICU patients have been reported, and cases observed at both low and high levels of heparin exposure (eg, venous access device line flushes and supratherapeutic doses associated with hemodialysis and during cardiopulmonary bypass). Monitor platelet count closely; if HIT develops, consider alternate anticoagulation therapy (eg, danaparoid,  argatroban) (ACCP [Monagle 2012]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Heparin resistance should be suspected in pediatric patients if unable to achieve an ACT &gt;300 seconds after administration of &gt;600 units/kg (ACCP [Giglia 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299438\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178720\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13349&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Heparin may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Heparin may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Heparin may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithrombin: May enhance the anticoagulant effect of Heparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: May enhance the anticoagulant effect of Heparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: Heparin may enhance the hyperkalemic effect of Canagliflozin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Heparin may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: May diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oritavancin: May diminish the therapeutic effect of Heparin. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: Heparin may increase the serum concentration of Palifermin.  Management: If heparin is used to maintain an intravenous line, rinse the line with saline prior to and after palifermin administration.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the anticoagulant effect of Heparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: Heparin may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Heparin may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.  Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Streptokinase: May enhance the anticoagulant effect of Heparin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Heparin. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178723\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6481836\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Increased resorptions were observed in some animal reproduction studies. Heparin does not cross the placenta. Heparin may be used for the prevention and treatment of thromboembolism in pregnant women; however the use of low molecular weight heparin (LMWH) is preferred. Twice-daily heparin should be discontinued prior to induction of labor or a planned cesarean delivery. In pregnant women with mechanical heart valves, adjusted-dose LMWH or adjusted-dose heparin may be used throughout pregnancy or until week 13 of gestation when therapy can be changed to warfarin. LMWH or heparin should be resumed close to delivery. In women who are at a very high risk for thromboembolism (older generation prosthesis in mitral position or history of thromboembolism), warfarin can be used throughout pregnancy and replaced with LMWH or heparin near term; the use of low-dose aspirin is also recommended. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some products contain benzyl alcohol as a preservative; their use in pregnant women is contraindicated by some manufacturers; use of a preservative free formulation is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053160\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin, hematocrit, signs of bleeding; fecal occult blood test; aPTT (or antifactor Xa activity levels) or ACT depending upon indication</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Platelet counts should be routinely monitored (eg, every 2 to 3 days on days 4 to 14 of heparin therapy) when the risk of HIT is &gt;1% (eg, receiving therapeutic dose heparin, postoperative antithrombotic prophylaxis), if the patient has received heparin or low molecular weight heparin (eg, enoxaparin) within the past 100 days, if preexposure history is uncertain, or if anaphylactoid reaction to heparin occurs. When the risk of HIT is &lt;1% (eg, medical/obstetrical patients receiving heparin flushes), routine platelet count monitoring is not recommended (Guyatt 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients on ECMO, ACT should be checked hourly while patient is on ECMO (AHA [Giglia 2013]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For intermittent IV injections, aPTT is measured 3.5 to 4 hours after IV injection.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Continuous IV infusion is preferred over IV intermittent injections. For full-dose heparin (ie, nonlow-dose), the dose should be titrated according to aPTT results. For anticoagulation, an aPTT 1.5 to 2.5 times normal is usually desired. Because of variation among hospitals in the control aPTT values, nomograms should be established at each institution, designed to achieve aPTT values in the target range (eg, for a control aPTT of 30 seconds, the target range [1.5 to 2.5 times control] would be 45 to 75 seconds). Measurements should be made prior to heparin therapy, 6 hours (pediatric: 4 hours) after initiation, and 6 hours (pediatric: 4 hours) after any dosage change, and should be used to adjust the heparin infusion until the aPTT exhibits a therapeutic level. When two consecutive aPTT values are therapeutic, subsequent measurements may be made every 24 hours, and if necessary, dose adjustment carried out. In addition, a significant change in the patient's clinical condition (eg, recurrent ischemia, bleeding, hypotension) should prompt an immediate aPTT determination, followed by dose adjustment if necessary. In general, may increase or decrease infusion by 2 to 4 units/kg/hour dependent upon aPTT.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Heparin infusion dose adjustment: A number of adult dose-adjustment nomograms have been developed which target an aPTT range of 1.5 to 2.5 times control (Cruickshank 1991; Flaker 1994; Hull 1992; Raschke 1993). However, institution-specific and indication-specific nomograms should be consulted for dose adjustment. <b>Note</b>: aPTT values vary throughout the day with maximum values occurring during the night (Decousus 1985).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053164\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venous thromboembolism: Heparin: pediatric patients: 0.35 to 0.7 unit/mL; adults: 0.3 to 0.7 unit/mL anti-Xa activity (by chromogenic assay) or 0.2 to 0.4 unit/mL (by protamine titration); aPTT: 1.5 to 2.5 times control (usually reflects an aPTT of 60 to 85 seconds) (Garcia 2012; ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ECMO anticoagulation: Maintain the ACT between 180 and 220 seconds; additional monitoring targets for heparin therapy are prolongation of the PTT to 1.5 to 2.5 times the control value and an anti-Xa level of 0.3 to 0.7 units/mL (AHA [Giglia 2013])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178714\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potentiates the action of antithrombin III and thereby inactivates thrombin (as well as activated coagulation factors IX, X, XI, XII, and plasmin) and prevents the conversion of fibrinogen to fibrin; heparin also stimulates release of lipoprotein lipase (lipoprotein lipase hydrolyzes triglycerides to glycerol and free fatty acids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178734\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Increased interpatient variability of pharmacokinetic parameters in pediatric patients compared to adults; however, age-related decreases in volume of distribution and clearance with increasing pediatric patient age have been reported (ACCP [Monagle 2012]; McDonald 1981).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Anticoagulation: IV: Immediate; SubQ: ~20 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral, rectal: Erratic at best from these routes of administration; SubQ absorption is also erratic, but considered acceptable for prophylactic use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates (data based on single dose of 100 units/kg within 4 hours of birth) (McDonald 1981): Inversely proportional to gestational age</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 25 to 28 weeks: 81 &plusmn; 41 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 29 to 32 weeks: 73.3 &plusmn; 24.8 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 33 to 36 weeks: 57.8 &plusmn; 32.2 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Following a single 75 unit/kg dose: 36.6 &plusmn; 7.4 mL/kg (McDonald 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Complex; thought to occur by depolymerization and desulphation via the reticuloendothelial system primarily in the liver and spleen (ACCP [Garcia 2012]; Dawes 1979; Estes 1980; Kandrotas 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Age-related: Shorter half-life reported in premature neonates compared to adult patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates GA 25 to 36 weeks (data based on single dose of 100 units/kg within 4 hours of birth): Mean range: 35.5 to 41.6 minutes (McDonald 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose-dependent: IV bolus: 25 units/kg: 30 minutes (Bjornsson 1982); 100 units/kg: 60 minutes (de Swart 1982); 400 units/kg: 150 minutes (Olsson 1963)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mean: 1.5 hours; Range: 1 to 2 hours; affected by obesity, renal function, malignancy, presence of pulmonary embolism, and infections</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> At therapeutic doses, elimination occurs rapidly via nonrenal mechanisms. With very high doses, renal elimination may play more of a role; however, dosage adjustment remains unnecessary for patients with renal impairment (Kandrotas 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (small amounts as unchanged drug); <b>Note: </b>At therapeutic doses, elimination occurs rapidly via nonrenal mechanisms. With very high doses, renal elimination may play more of a role; however, dosage adjustment remains unnecessary for patients with renal impairment (Kandrotas 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Age-related changes; within neonatal population, slower clearance with lower GA; however, when compared to adults, the overall clearance in neonatal and pediatric patients is faster than adults (ACCP [Monagle 2012 ]; McDonald 1981)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053171\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Updates to the United States Pharmacopeia (USP) heparin monograph were made in response to over 200 deaths linked to contaminated heparin products in 2007-2008. Serious adverse effects (including hypersensitivity reactions) were associated with a heparin-like contaminant (oversulfated chondroitin sulfate). At the time, the available quality assurance tests did not test for oversulfated chondroitin sulfate. Effective October 1, 2009, a new reference standard for heparin and a new test to determine potency (the chromogenic antifactor IIa test) were established by USP. The updated USP heparin monograph also harmonized the USP unit with the WHO international standard (IS) unit (ie, international unit). The new standard may result in a 10% reduction in potency for heparin marketed in the United States. The FDA has requested that all manufacturers differentiate (from &quot;old&quot; heparin products) heparin products manufactured by the new standards. The labels of products manufactured according to the new standard will have an &quot;N&quot; in the lot number or following the expiration date. Additionally, products manufactured by Hospira may be identified by the number &quot;82&quot; or higher (eg, 83, 84) at the beginning of their lot numbers. For therapeutic use, practitioners may or may not notice that larger doses of heparin are required to achieve &quot;therapeutic&quot; activity of anticoagulation. The impact of this change in potency should be less significant when heparin is administered by subcutaneous injection due to low and variable bioavailability. Heparin dosing should always be individualized according to the patient-specific clinical situation. Appropriate clinical judgment is essential in determining heparin dosage (Smythe 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524629\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin (Porcine) in NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500UT/150ML 0.9% (150 mL): $23.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin (Porcine) in NaCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 unit/mL 0.9% (500 mL): $5.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 unit/mL 0.45% (250 mL): $8.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 unit/mL 0.45% (250 mL): $10.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin (Porcine) in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100UT/100ML 0.45% (100 mL): $10.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250UT/250ML 0.45% (250 mL): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500UT/250ML 0.45% (250 mL): $14.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000UNIT/L 0.9% (1000 mL): $18.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000UT/500ML 0.9% (500 mL): $15.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000UNIT/L 0.9% (1000 mL): $21.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000UT/500ML 0.9% (500 mL): $15.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6000UNIT/L 0.9% (1000 mL): $20.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15000UT/500ML 0.9% (500 mL): $21.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000UT/250ML 0.45% (250 mL): $20.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000UT/250ML 0.9% (250 mL): $19.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000UT/500ML 0.9% (500 mL): $21.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30000UNIT/L 0.9% (1000 mL): $23.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Lock Flush Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 units/mL (3 mL): $3.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 units/mL (5 mL): $3.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (5 mL): $2.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Sod (Porcine) in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (250 mL): $20.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Sodium (Porcine) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 units/mL (10 mL): $3.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 units/mL (1 mL): $1.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 units/mL (1 mL): $2.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000 units/mL (1 mL): $12.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Sodium (Porcine) PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 units/0.5 mL (0.5 mL): $6.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Sodium Lock Flush Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (5 mL): $3.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Heparin (Porcine) in NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UNT/20ML 0.9% (20 mL): $9.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50UNT/50ML 0.45% (50 mL): $10.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50UNT/50ML 0.9% (50 mL): $10.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Heparin Sodium (Porcine) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000UNIT/3ML (3 mL): $5.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 unit/5 mL (5 mL): $6.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 unit/10 mL (10 mL): $9.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178738\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agglutek (TW);</li>\n      <li>Anticlot (VN);</li>\n      <li>Caprin (IN);</li>\n      <li>Coaparin (PL);</li>\n      <li>Hemastat (PH);</li>\n      <li>Hemonor (PE);</li>\n      <li>Hepaflex (FI, NO);</li>\n      <li>Heparen (LK);</li>\n      <li>Heparin (AT, BF, BG, BJ, CH, CI, CZ, DE, ET, FI, GB, GH, GM, GN, GR, IL, KE, LR, MA, ML, MR, MU, MW, NE, NG, NO, SC, SD, SE, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Heparin Injection B.P. (AU);</li>\n      <li>Heparin Leo (DK, HK, ID, MY, PH, TW);</li>\n      <li>Heparin Novo (TW);</li>\n      <li>Heparin Sodium B Braun (ID, MY);</li>\n      <li>Heparina (ES);</li>\n      <li>Heparine (BE, NL);</li>\n      <li>Heparine Choay (FR);</li>\n      <li>Heparine Novo (BE, NL);</li>\n      <li>Heprin (PH);</li>\n      <li>Hepsal (MT, SA, SG);</li>\n      <li>Heptin (PH);</li>\n      <li>Hiruderm (HK);</li>\n      <li>Inhepar (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Inviclot (ID);</li>\n      <li>Kabihep (PH);</li>\n      <li>Lioton (RU);</li>\n      <li>Liquemin (DE, IT);</li>\n      <li>Liquemine (BE, TR);</li>\n      <li>Minihep (AE, QA);</li>\n      <li>Monoparin (QA, SA);</li>\n      <li>Multiparin (NZ, PK);</li>\n      <li>Nuparin (PH);</li>\n      <li>Proparin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Rhoneparina (PY);</li>\n      <li>Thrombophob (DE);</li>\n      <li>Thromboreduct (DE);</li>\n      <li>Unihep (AE, QA);</li>\n      <li>Wellparin (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrew M, Marzinotto V, Massicotte P, et al, &ldquo;Heparin Therapy in Pediatric Patients: A Prospective Cohort Study,&rdquo; <i>Pediatr Res</i>, 1994, 35(1):78-83. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/ 8134203 /pubmed\" target=\"_blank\" id=\" 8134203 \"> 8134203 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bjornsson T, Wolfram B, Kitchell B. Heparin kinetics determined by three assay methods. <i>Clin Pharmacol Ther</i>. 1982;31(1):104&ndash;113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/7053298/pubmed\" target=\"_blank\" id=\"7053298\">7053298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butt W, Shann F, McDonnell G, Hudson I. Effect of heparin concentration and infusion rate on the patency of arterial catheters. <i>Crit Care Med</i>. 1987;15(3):230-232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/3545674 /pubmed\" target=\"_blank\" id=\"3545674 \">3545674 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corkin MR, ed. <i>Pediatric Nutrition Support Core Curriculum</i>. 2nd edition. Silver Sprin, MD: American Society for Parenteral and Enteral Nutrition; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conway MA, McCollom C, Bannon C. Central venous catheter flushing recommendations: a systematic evidence-based practice review. <i>J Pediatr Oncol Nurs</i>. 2014;31(4):185-190.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24794887 /pubmed\" target=\"_blank\" id=\"24794887 \">24794887 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cruickshank MK, Levine MN, Hirsh J, et al, &ldquo;A Standard Heparin Nomogram for the Management of Heparin Therapy,&rdquo; <i>Arch Intern Med</i>, 1991, 151(2):333-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/1789820/pubmed\" target=\"_blank\" id=\"1789820\">1789820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, Dougherty JA, Nguyen PH, et al, &ldquo;Heparin-Induced Thrombocytopenia: Treatment Options and Special Considerations,&rdquo; <i>Pharmacotherapy</i>, 2007, 27(4):564-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/17381384/pubmed\" target=\"_blank\" id=\"17381384\">17381384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Decousus HA, Croze M, Levi FA, et al, &ldquo;Circadian Changes in Anticoagulant Effect of Heparin Infused at a Constant Rate,&rdquo; <i>Br Med J (Clin Res Ed)</i>, 1985, 290(6465):341-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/3917812/pubmed\" target=\"_blank\" id=\"3917812\">3917812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Swart C, Nijmeyer B, Roelofs J, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. <i>Blood</i>. 1982;60(6):1251&ndash;1258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/7139119/pubmed\" target=\"_blank\" id=\"7139119\">7139119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaker GC, Bartolozzi J, Davis V, et al, &ldquo;Use of a Standardized Heparin Nomogram to Achieve Therapeutic Anticoagulation after Thrombolytic Therapy in Myocardial Infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction,&rdquo; <i>Arch Intern Med</i>, 1994, 154(13):1492-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/8018004/pubmed\" target=\"_blank\" id=\"8018004\">8018004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freed MD, Keane JF, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. <i>Circulation</i>. 1974;50(3):565-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/4607271 /pubmed\" target=\"_blank\" id=\"4607271 \">4607271 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(24):2622-2703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/24226806 /pubmed\" target=\"_blank\" id=\"24226806 \">24226806 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodman SG, Menon V, Cannon CP, et al, &quot;Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):708S-775S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/18574277 /pubmed\" target=\"_blank\" id=\"18574277 \">18574277 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harrington RA, Becker RC, Cannon CP, et al, &quot;Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):670S-707S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/18574276 /pubmed\" target=\"_blank\" id=\"18574276 \">18574276 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsh J, Bauer KA, Donati MB, et al, &quot;Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):141S-159S. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/18574264/pubmed\" target=\"_blank\" id=\"18574264\">18574264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsh J, Guyatt G, Albers GW, et al, &quot;Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):71-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/18574259/pubmed\" target=\"_blank\" id=\"18574259\">18574259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hull RD, Raskob GE, Rosenbloom D, et al, &ldquo;Optimal Therapeutic Level of Heparin Therapy in Patients with Venous Thromboembolism,&rdquo; <i>Arch Intern Med</i>, 1992, 152(8):1589-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/1497392/pubmed\" target=\"_blank\" id=\"1497392\">1497392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. <i>Clin Pharmacokinet</i>. 1992;22(5):359-374.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/1505142/pubmed\" target=\"_blank\" id=\"1505142\">1505142</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Kahn SR, Agnelli G, et al, &quot;Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):454S-545S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/18574272/pubmed\" target=\"_blank\" id=\"18574272\">18574272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee OK, Johnston L. A systematic review for effective management of central venous catheters and catheter sites in acute care paediatric patients. <i>Worldviews Evid Based Nurs</i>. 2005;2(1):4-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/17040550 /pubmed\" target=\"_blank\" id=\"17040550 \">17040550 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. <i>Pediatr Res</i>. 1981;15(7):1015-1018. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/7254945 /pubmed\" target=\"_blank\" id=\"7254945 \">7254945 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):e737S-801S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22315277 /pubmed\" target=\"_blank\" id=\"22315277 \">22315277 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newall F, Johnston L, Ignjatovic V, et al, &quot;Unfractionated Heparin Therapy in Infants and Children,&quot; <i>Pediatrics</i>, 2009, 123(3):e510-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/19221154 /pubmed\" target=\"_blank\" id=\"19221154 \">19221154 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin: An experimental study on dogs and humans. <i>Acta Med Scand</i>. 1963;173:619&ndash;630.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/13940090/pubmed\" target=\"_blank\" id=\"13940090\">13940090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raschke RA, Reilly BM, Guidry JR, et al, &ldquo;The Weight-Based Heparin Dosing Nomogram Compared With a &ldquo;Standard Care&rdquo; Nomogram: A Randomized Controlled Trial,&rdquo; <i>Ann Intern Med</i>, 1993, 119(9):874-81. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smythe MA, Nutescu EA, and Wittkowsky AK, &quot;Changes in the USP Heparin Monograph and Implications for Clinicians,&quot; <i>Pharmacotherapy</i>, 2010, 30(5):428-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/20411994/pubmed\" target=\"_blank\" id=\"20411994\">20411994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warkentin TE and Kelton JG, &ldquo;Temporal Aspects of Heparin-Induced Thrombocytopenia,&rdquo; <i>N Engl J Med</i>, 2001, 344(17):1286-92. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-pediatric-drug-information/abstract-text/11320387/pubmed\" target=\"_blank\" id=\"11320387\">11320387</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13349 Version 190.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178752\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F178753\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053161\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442594\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053153\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178727\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F178711\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053166\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14472659\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472658\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F178745\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053165\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F178805\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178802\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178735\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178715\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022558\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299438\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178720\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178723\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6481836\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053160\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1053164\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178714\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F178734\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1053171\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524629\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178738\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13349|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=heparin-unfractionated-drug-information\" class=\"drug drug_general\">Heparin (unfractionated): Drug information</a></li><li><a href=\"topic.htm?path=heparin-unfractionated-patient-drug-information\" class=\"drug drug_patient\">Heparin (unfractionated): Patient drug information</a></li></ul></div></div>","javascript":null}